Saturday, October 31, 2026

How We Source Explore Search

#DCO

26 articles

Equus Total Return And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Equus Total Return And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Feb 25, 2024

Amphastar Pharmaceuticals And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Amphastar Pharmaceuticals And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Feb 7, 2024

Sterling Construction Company And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Sterling Construction Company And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jan 29, 2024

DHT Holdings And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

DHT Holdings And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jan 3, 2024

Capital Southwest Corporation And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Capital Southwest Corporation And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Dec 9, 2023

Huazhu Group And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Huazhu Group And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Oct 30, 2023

Trip.com And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Trip.com And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Oct 27, 2023

Rexford Industrial Realty And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Rexford Industrial Realty And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Oct 14, 2023

Novo Nordisk A/S And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Novo Nordisk A/S And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Oct 4, 2023

Sapiens International Corporation N.V. And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Sapiens International Corporation N.V. And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Sep 21, 2023

Hallador Energy Company And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Hallador Energy Company And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Aug 21, 2023

Columbia Banking System And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Columbia Banking System And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Aug 14, 2023

Magellan Midstream Partners L.P. Limited Partnership And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Magellan Midstream Partners L.P. Limited Partnership And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Aug 9, 2023

Dorian LPG Ltd. And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Dorian LPG Ltd. And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Aug 5, 2023

Main Street Capital Corporation And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Main Street Capital Corporation And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Aug 1, 2023

SSR Mining And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

SSR Mining And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jul 23, 2023

Catalyst Pharmaceuticals And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Catalyst Pharmaceuticals And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jul 11, 2023

Live Nation Entertainment And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Live Nation Entertainment And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jul 8, 2023

HBT Financial And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

HBT Financial And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jun 17, 2023

Realty Income Corporation And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Realty Income Corporation And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team•Jun 15, 2023

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings

ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,525 source documents archived

Query this data → isubstrate.com